Lipoprotein lipase (LPL) is the central enzyme in plasma triglyceride hydrolysis. In vitro studies have shown that LPL also can enhance lipoprotein uptake into cells via pathways that are independent of catalytic activity but require LPL as a molecular bridge between lipoproteins and proteoglycans or receptors. To investigate whether this bridging function occurs in vivo, two transgenic mouse l...

BACKGROUND AND OBJECTIVE Rapidly establishing the cause of neonatal cholestasis is an urgent matter. The aim of this study was to report on the prevalence and mortality of the diverse disorders causing neonatal cholestasis in an academic center in Germany. METHODS Clinical chemistry and cause of disease were retrospectively analyzed in 82 infants (male n = 42, 51%) that had presented with neo...

Background The identification of new exploitable molecular pathogeneses (beyond the conventional amyloid hypothesis) for Alzheimer’s disease (AD) is a continuing neurotherapeutic priority, and has yielded range mechanistic proposals including immunopathy, gliopathy, mitochondriopathy, synaptopathy. However, as these hypotheses emerge, they are often regarded mutually exclusive even in competiti...

Physicians are among those prescribed statins and therefore, subject to potential statin adverse effects (AEs). There is little information on the impact of statin AEs on physicians affected by them. We sought to assess the character and impact of statin AEs occurring in physicians and retired physicians, and to ascertain whether/how personal experience of AEs moderated physicians' attitude tow...

Mitochondrial disorders are multisystem diseases that can be caused by any defect in the energy (ATP) generating pathways in the mitochondria. The difficulty in diagnosing mitochondrial diseases on the molecular level arises from several obstacles: (A) About 1000 genes are involved in the biogenesis of mitochondria. The dysfunction of each of them may potentially cause mitochondriopathy. (B) Th...

Anthracyclines and many other antitumor drugs induce cardiotoxicity that occurs “on treatment” or long after completing chemotherapy. Dose reductions limit the incidence of early cardiac events but not that of delayed sequelae, possibly indicating that any dose level of antitumor drugs would prime the heart to damage from sequential stressors. Drugs targeted at tumor-specific moieties raised ho...